Core Viewpoint - The announcement highlights the approval of a new veterinary drug, specifically an inactivated vaccine for porcine parvovirus, developed by the company's subsidiary and partners, indicating a significant advancement in the veterinary pharmaceutical sector [1]. Group 1 - The company, BioShares, announced the approval of a new veterinary drug by the Ministry of Agriculture and Rural Affairs [1]. - The approved product is an inactivated vaccine for porcine parvovirus, known as rPP03 strain [1]. - The vaccine was developed in collaboration with the company's wholly-owned subsidiary, Yangzhou Youbang Biological Pharmaceutical Co., Ltd., and Jinyu Baoling Biological Pharmaceutical Co., Ltd., among others [1].